Cell and Gene Commercialization

31. Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness 5/8/2026

    Mainstream biopharma’s commercialization playbook isn’t working for cell and gene therapies. Orgs that invest in scalable platforms (and more) will see better success.

32. 9 Logistics And Distribution Recommendations For CGTs 5/6/2026

    Cell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.

33. Materials Matter: Reframing Raw Material Strategy In Cell And Gene Therapy Development 5/1/2026

    Scaling iPSC-based therapies from lab to CGMP manufacturing demands tightly controlled cryopreservation, risk-based QC, and strategic automation to preserve cell viability, consistency, and regulatory readiness.

34. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.

35. Cell And Gene Therapy CDMOs: On The Path To $75 Billion in Services? 4/30/2026

    Cell and gene therapy (CGT) developers – and thus their service providers – have had their share of ups and downs. But what do the promise and uneven realities of these therapies add up to in the development and manufacturing outsourcing sector? According to a Towards Healthcare report, despite the bumps in the road, in 2025 the global CGT CDMO market grew to $8.2 billion. What of future predictions? Here's a detailed analysis.

36. How AI Could Clear Logistics Roadblocks Limiting Patient Access To CGT 4/23/2026

    Patient access often gets mischaracterized solely as a cost and pricing issue. A discussion among industry leaders reaches a deeper, more complex conclusion.

37. Mapping Candel Therapeutics' Sprint To The BLA Finish Line 4/22/2026

    Leaders from the adenovirus/prodrug developer discuss the complex balancing act of preparing to scale up for commercial manufacturing without overextension.

38. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

39. Overcome Patient-Level Access Barriers For New Medicine 3/23/2026

    Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.

40. Industry Innovators: APAC's Sharp Advanced Therapeutics Edge 3/17/2026

    APAC is rapidly advancing its role in the global therapeutics landscape, fueled by faster development models. Learn how this momentum is reshaping expectations for innovation and commercialization.